US flags Alibaba, BYD over alleged Chinese military links before key summit - Yes Punjab News US adds Alibaba, BYD, Baidu to military-linked Chinese companies list, raising tensions ahead of Xi-Trump Beijing meeting.

US flags Alibaba, BYD over alleged Chinese military links before key summit yespunjab.com?p=217322

#USChinaTensions #Pentagon1260HList #Alibaba #BYD #Baidu #ChineseMilitaryCompanies #NationalSecurity #WuXiAppTec #RoboSense #BOETechnology #TradeNews

WuXi AppTec to raise $981 mln via share placement to support expansion Investing.com-- WuXi AppTec (SS:603259) said on Thursday it will raise HK$7.70 billion ($981 million) through a Hong Kong share placement to support its global expansion and capacity building. The Chinese pharmaceutical services firm will issue 73.8 million new H-shares at HK$104.27 each, a 6.9% discount to its July 30 closing price. The placement represents roughly 2.51% of the company’s enlarged share capital and is expected to be allocated to at least six institutional investors, the company said in a statement. Net proceeds of around HK$7.65 billion will go primarily toward overseas growth, with 90% allocated to international expansion and capacity construction, and the remainder for general corporate purposes, Wuxi said.

Click Subscribe #WuXiAppTec #SharePlacement #Investment #BusinessExpansion #MarketNews

Wuxi AppTec sees strong profit growth for 1H25 Investing.com-- Chinese pharmaceutical firm WuXi AppTec (SS:603259) expects a sharp rise in first-half profit, driven by robust demand for its contract research and manufacturing services. The company on Thursday projected that net profit attributable for the six months ending June 30 would surge 101.9% year-on-year to 8.56 billion yuan ($1.19 billion), boosted by a one-time gain from the partial sale of shares in subsidiary WuXi XDC Cayman. Adjusted net profit, excluding one-off items, is forecast to jump 44.4% to 6.31 billion yuan, reflecting strong performance in its integrated CRDMO (Contract Research, Development and Manufacturing Organization) business model. Revenue for the first half is estimated to grow 20.6% to 20.8 billion yuan, with core operations showing a 24.2% increase. The company attributed the growth to enhanced operational efficiency and expanded capacity to meet rising global demand for drug development services. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if 603259 is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #WuXiAppTec #ProfitGrowth #Pharmaceuticals #Investing #StockMarket

China’s WuXi AppTec rallies as strong Q1 earnings indicate minimal tariff impact Blog Mobile Portfolio Widgets About Us Advertise Help & Support Authors Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #WuXiAppTec #Q1Earnings #Pharmaceuticals #ChinaMarket #StockMarket

NAMSA will acquire WuXi AppTec facilities in Minnesota and Georgia. More on how the acquisition solidifies NAMSA's position as the leader in medtech testing and clinical research: https://buff.ly/4388rjX #tmdmag #medtech #manufacturing #namsa #wuxiapptec #acquisition

Thumbnail for the video

🇨🇳 How is China Challenging US Biotech Limits? #China #Biotech

#China #Biotech #WuXiAppTec #Innovation #Healthcare #Pharma #GeneTherapy #CellTherapy #GlobalTrade #Economy